Blueprint
UNITED
STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
September 6, 2017
Date of report (date of earliest event
reported)
MusclePharm
Corporation
(Exact name of registrant as specified in its
charter)
|
Nevada
|
|
000-53166
|
|
77-0664193
|
|
(State or other jurisdictions ofincorporation
or organization)
|
|
(CommissionFile
Number)
|
|
(I.R.S. EmployerIdentification
Nos.)
|
4721 Ironton
Street, Building A Denver, Colorado
80239
(Address of principal executive offices) (Zip
Code)
(303) 396-6100
(Registrant’s telephone number, including area
code)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrants under any of the following
provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of
the Securities Act of 1933 (230.405 of this chapter) or Rule
12b-2of the Securities Exchange Act of 1934 (§ 240 12b-2 of this
chapter).
Emerging Growth Company
☐
If an emerging growth company,
indicate by a check mark if the registrant has elected not to use
the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐
On September 6, 2017, counsel to
Ryan Drexler, the Chairman of the Board, Chief Executive Officer
and President of MusclePharm Corporation (the
“Company”), sent to counsel to the Company a letter
proposing the extension and restructuring of Mr. Drexler’s
existing secured promissory notes with the Company. A copy of
the letter is attached as Exhibit 99.1 to this Form 8-K.
The form of Indemnification
Agreement filed as Exhibit 10.1 to this Current Report on Form 8-K
replaces the form of Indemnification Agreement previously filed as
Exhibit 10.1 to the Form 8-K filed by the Company on August 27,
2012. The Company intends to enter into the new form of
Indemnification Agreement with each of its
directors.
Item 9.01
Financial
Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
|
Form of
Indemnification Agreement.
|
|
|
|
|
|
|
|
Letter from
counsel to Ryan Drexler to counsel to MusclePharm
Corporation.
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
MUSCLEPHARM CORPORATION
|
|
|
|
|
|
|
|
Date
|
By:
|
/s/ Ryan
Drexler
|
|
|
|
Name:
|
Ryan Drexler
|
|
|
|
Title:
|
Chief Executive Officer and
President
|
|
Date: September 8,
2017
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
|
Form of Indemnification
Agreement.
|
|
|
|
|
|
|
|
Letter from counsel to
Ryan Drexler to counsel to MusclePharm
Corporation.
|